Kumar Neil 4

4 · BridgeBio Pharma, Inc. · Filed Mar 19, 2026

AI-generated summary of this filing

Updated Mar 19, 2026

BridgeBio (BBIO) CEO Neil Kumar Receives Equity Awards

What Happened

Neil Kumar, CEO of BridgeBio Pharma, was granted two equity awards on March 17, 2026: 40,570 derivative shares (option grant) and 104,313 Restricted Stock Units (RSUs). Both grants are reported at an acquisition price of $0.00. These were reported on a Form 4 filed March 19, 2026.
This was an award/grant (transaction code A), not an open‑market buy or sale. No cash changed hands at grant; the awards are contingent on future vesting and continued service.

Key Details

Transaction date: 2026-03-17; Form 4 filed: 2026-03-19 (timely).
Grants: 40,570 (derivative option) and 104,313 RSUs; both reported at $0.00.
Total shares awarded: 144,883.
Vesting: For the option (F1) and RSUs (F3) the schedule is 1/16th vesting on May 16, 2026, then 1/16th vesting quarterly thereafter, subject to continued service. RSUs represent a contingent right to one share each (F2) and the RSUs have no expiration date.
Shares owned after the transaction are not specified in the provided excerpt.
No 10b5-1 plan, tax‑withholding, or late‑filing notes are indicated in the excerpt.

Context

These grants are typical executive compensation: RSUs convert into shares on vesting, and the option becomes exercisable per the vesting schedule. Because these are awards (not purchases or sales), they do not reflect an immediate cash investment or divestment by the CEO.

Form 4

Period: 2026-03-17

DirectorChief Executive Officer

Transactions

Award
Stock Option (Right to Buy)
[F1]
2026-03-17+40,570→ 40,570 total
Exercise: $70.94Exp: 2036-03-16→ Common Stock (40,570 underlying)
Award
Restricted Stock Units
[F2][F3]
2026-03-17+104,313→ 104,313 total
→ Common Stock (104,313 underlying)

Footnotes (3)

[F1]1/16th of the shares subject to this option vest and become exercisable on May 16, 2026, and thereafter, 1/16th of the shares subject to this option will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.
[F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
[F3]The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Signature

/s/ Will Solis, Attorney-in-Fact|2026-03-19

1 file